8-K: CG Oncology Announces Positive Final Results from Phase 2 CORE-001 Study for Bladder Cancer Treatment

CG Oncology reported positive final results from its Phase 2 CORE-001 trial, showing a significant complete response rate for its bladder cancer therapy, cretostimogene, in combination with pembrolizumab.

Summary

• CG Oncology announced final results from the Phase 2 CORE-001 clinical trial of cretostimogene in combination with pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS).
• The study showed a 54% complete response (CR) rate at 24 months in the intention-to-treat (ITT) population.
• At 12 months, the CR rate was 57%, and at any time, it reached 83%.
• 95% of patients who achieved a CR at 12 months maintained it for another 12 months.
• The median duration of response (DoR) has not been reached but exceeds 21 months.
• Progression-free survival (PFS) at 24 months was 100%, with no patients progressing to muscle-invasive cancer or metastatic disease.
• Cystectomy-free survival (CFS) at 24 months was 80%, and for patients in CR, it was 100%.
• Treatment-related adverse events (TRAEs) were consistent with the individual agents and showed no synergistic toxicity.
• These results will be presented at the ASCO 2024 Annual Meeting.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results with high efficacy and good safety, suggesting a strong potential for the drug. The high complete response rate, progression-free survival, and duration of response are all very encouraging.

Positives

• The 54% complete response rate at 24 months is a significant positive outcome for patients with this type of bladder cancer.
• The high rate of patients maintaining a complete response from 12 to 24 months indicates the durability of the treatment.
• The 100% progression-free survival at 24 months is a very positive result, showing the treatment's effectiveness in preventing disease progression.
• The 100% cystectomy-free survival for patients in complete response at 24 months suggests the treatment can help patients avoid radical surgery.
• The treatment was well-tolerated, with no synergistic toxicity observed.

Risks

• The reported data is based on preliminary analysis and is subject to further audit and verification, which could lead to changes in the final data.
• Additional patient data may be inconsistent with the current results, and further analysis may lead to different conclusions.
• Results from earlier clinical trials and preclinical studies may not be predictive of future results.
• Unexpected adverse side effects or inadequate efficacy of cretostimogene may limit its development, regulatory approval, and commercialization.
• There are potential delays in the commencement, enrollment, and completion of clinical trials.

Future Outlook

CG Oncology plans to incorporate the findings from the CORE-001 trial into its planned CORE-008 trial in high-risk NMIBC and is on track for a regulatory approval submission for BOND-003.

Management Comments

• Vijay Kasturi, MD, Chief Medical Officer, stated that they are encouraged by the final safety and efficacy data from the CORE-001 Phase 2 trial, which showed a class-leading complete response and duration of response compared to existing FDA-approved therapies and other investigational candidates.
• Management believes these results support further investigation of cretostimogene in combination with checkpoint inhibitors.

Industry Context

The announcement is significant as it addresses the unmet need for new treatments for bladder cancer, particularly in patients who are unresponsive to BCG therapy. The results position cretostimogene as a potential backbone therapy for NMIBC, which is a competitive area with several other companies developing new treatments.

Comparison to Industry Standards

• The 54% complete response rate at 24 months in the CORE-001 trial is competitive with other treatments for BCG-unresponsive NMIBC.
• Keytruda (pembrolizumab) monotherapy has shown lower complete response rates in similar patient populations.
• Other investigational therapies in this space include gene therapies and other immunotherapies, but the combination of cretostimogene and pembrolizumab appears to be showing promising results.
• The 100% progression-free survival at 24 months is a notable achievement compared to historical data for this patient population.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results.
• Patients with BCG-unresponsive, high-risk NMIBC may benefit from this potential new treatment option.
• The positive results may enhance the company's reputation and attract potential partners or investors.
• Employees may be motivated by the positive progress of the company's lead drug candidate.

Next Steps

• CG Oncology plans to present the CORE-001 trial results at the ASCO 2024 Annual Meeting.
• The company plans to incorporate these findings into its planned CORE-008 trial in high-risk NMIBC.
• Topline data from the Phase 3 BOND-003 trial is expected by the end of 2024.
• The company is on track for a regulatory approval submission.

Key Dates

Keywords

cretostimogene, pembrolizumab, bladder cancer, NMIBC, oncolytic immunotherapy, complete response, clinical trial, CORE-001, ASCO, BCG-unresponsive